CN108752424A - A kind of Antigenic Peptide chain group for treating tumour and its application in drug - Google Patents
A kind of Antigenic Peptide chain group for treating tumour and its application in drug Download PDFInfo
- Publication number
- CN108752424A CN108752424A CN201810561361.1A CN201810561361A CN108752424A CN 108752424 A CN108752424 A CN 108752424A CN 201810561361 A CN201810561361 A CN 201810561361A CN 108752424 A CN108752424 A CN 108752424A
- Authority
- CN
- China
- Prior art keywords
- prt
- artificial sequence
- lys
- glu
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 53
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 36
- 230000000890 antigenic effect Effects 0.000 title claims abstract description 33
- 239000003814 drug Substances 0.000 title abstract description 35
- 229940079593 drug Drugs 0.000 title abstract description 30
- 238000011282 treatment Methods 0.000 claims abstract description 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 15
- 239000000853 adhesive Substances 0.000 claims description 4
- 230000001070 adhesive effect Effects 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000013355 food flavoring agent Nutrition 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000007900 aqueous suspension Substances 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 20
- 230000002147 killing effect Effects 0.000 abstract description 14
- 210000004881 tumor cell Anatomy 0.000 abstract description 12
- 210000004443 dendritic cell Anatomy 0.000 abstract description 10
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract description 5
- 230000000086 blastomogenic effect Effects 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- RZZMZYZXNJRPOJ-BJDJZHNGSA-N Ala-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](C)N RZZMZYZXNJRPOJ-BJDJZHNGSA-N 0.000 description 46
- 108010009298 lysylglutamic acid Proteins 0.000 description 33
- 108010026333 seryl-proline Proteins 0.000 description 25
- VUXIQSUQQYNLJP-XAVMHZPKSA-N Thr-Ser-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N)O VUXIQSUQQYNLJP-XAVMHZPKSA-N 0.000 description 22
- FYBSCGZLICNOBA-XQXXSGGOSA-N Glu-Ala-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FYBSCGZLICNOBA-XQXXSGGOSA-N 0.000 description 20
- CGOHAEBMDSEKFB-FXQIFTODSA-N Glu-Glu-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O CGOHAEBMDSEKFB-FXQIFTODSA-N 0.000 description 20
- NMZXJDSKEGFDLJ-DCAQKATOSA-N Ser-Pro-Lys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CO)N)C(=O)N[C@@H](CCCCN)C(=O)O NMZXJDSKEGFDLJ-DCAQKATOSA-N 0.000 description 20
- HPKSHFSEXICTLI-CIUDSAMLSA-N Arg-Glu-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O HPKSHFSEXICTLI-CIUDSAMLSA-N 0.000 description 18
- ADDYYRVQQZFIMW-MNXVOIDGSA-N Ile-Lys-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ADDYYRVQQZFIMW-MNXVOIDGSA-N 0.000 description 18
- XDKKMRPRRCOELJ-GUBZILKMSA-N Pro-Val-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 XDKKMRPRRCOELJ-GUBZILKMSA-N 0.000 description 17
- OFGUOWQVEGTVNU-DCAQKATOSA-N Pro-Lys-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O OFGUOWQVEGTVNU-DCAQKATOSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 13
- NZGTYCMLUGYMCV-XUXIUFHCSA-N Ile-Lys-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N NZGTYCMLUGYMCV-XUXIUFHCSA-N 0.000 description 12
- MLSUZXHSNRBDCI-CYDGBPFRSA-N Ile-Pro-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)O)N MLSUZXHSNRBDCI-CYDGBPFRSA-N 0.000 description 12
- 108010013835 arginine glutamate Proteins 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- KTXKIYXZQFWJKB-VZFHVOOUSA-N Ala-Thr-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O KTXKIYXZQFWJKB-VZFHVOOUSA-N 0.000 description 10
- OQXDUSZKISQQSS-GUBZILKMSA-N Glu-Lys-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O OQXDUSZKISQQSS-GUBZILKMSA-N 0.000 description 10
- MPOHDJKRBLVGCT-CIUDSAMLSA-N Lys-Ala-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N MPOHDJKRBLVGCT-CIUDSAMLSA-N 0.000 description 9
- IZJGPPIGYTVXLB-FQUUOJAGSA-N Lys-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N IZJGPPIGYTVXLB-FQUUOJAGSA-N 0.000 description 8
- 108010053725 prolylvaline Proteins 0.000 description 8
- 238000001514 detection method Methods 0.000 description 7
- XQGIRPGAVLFKBJ-CIUDSAMLSA-N Ala-Asn-Lys Chemical compound N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)O XQGIRPGAVLFKBJ-CIUDSAMLSA-N 0.000 description 6
- FBODFHMLALOPHP-GUBZILKMSA-N Asn-Lys-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O FBODFHMLALOPHP-GUBZILKMSA-N 0.000 description 6
- PHONAZGUEGIOEM-GLLZPBPUSA-N Glu-Glu-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PHONAZGUEGIOEM-GLLZPBPUSA-N 0.000 description 6
- UWKNTTJNVSYXPC-CIUDSAMLSA-N Lys-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN UWKNTTJNVSYXPC-CIUDSAMLSA-N 0.000 description 6
- PBIPLDMFHAICIP-DCAQKATOSA-N Lys-Glu-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PBIPLDMFHAICIP-DCAQKATOSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- JGAMUXDWYSXYLM-SRVKXCTJSA-N Lys-Arg-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O JGAMUXDWYSXYLM-SRVKXCTJSA-N 0.000 description 5
- QRVPEKJBBRYISE-XUXIUFHCSA-N Val-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)N QRVPEKJBBRYISE-XUXIUFHCSA-N 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 108010049041 glutamylalanine Proteins 0.000 description 5
- MXJYXYDREQWUMS-XKBZYTNZSA-N Glu-Thr-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O MXJYXYDREQWUMS-XKBZYTNZSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 208000037841 lung tumor Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 101100284398 Bos taurus BoLA-DQB gene Proteins 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000005909 tumor killing Effects 0.000 description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- NZGRHTKZFSVPAN-BIIVOSGPSA-N Ala-Ser-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N NZGRHTKZFSVPAN-BIIVOSGPSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 2
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 2
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 2
- 108010075704 HLA-A Antigens Proteins 0.000 description 2
- 108010058607 HLA-B Antigens Proteins 0.000 description 2
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 2
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- LPAJOCKCPRZEAG-MNXVOIDGSA-N Lys-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCCCN LPAJOCKCPRZEAG-MNXVOIDGSA-N 0.000 description 2
- IMAKMJCBYCSMHM-AVGNSLFASA-N Lys-Glu-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN IMAKMJCBYCSMHM-AVGNSLFASA-N 0.000 description 2
- NYTDJEZBAAFLLG-IHRRRGAJSA-N Lys-Val-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O NYTDJEZBAAFLLG-IHRRRGAJSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- -1 carrier Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- QXDXIXFSFHUYAX-MNXVOIDGSA-N Glu-Ile-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(O)=O QXDXIXFSFHUYAX-MNXVOIDGSA-N 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 1
- 102100036241 HLA class II histocompatibility antigen, DQ beta 1 chain Human genes 0.000 description 1
- 108010052199 HLA-C Antigens Proteins 0.000 description 1
- 108010065026 HLA-DQB1 antigen Proteins 0.000 description 1
- OUUCIIJSBIBCHB-ZPFDUUQYSA-N Ile-Leu-Asp Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O OUUCIIJSBIBCHB-ZPFDUUQYSA-N 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000000035 Osteochondroma Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 229940060265 aldara Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000012191 childhood neoplasm Diseases 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000004405 cytokine-induced killer cell Anatomy 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000026517 ureter neoplasm Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a kind of Antigenic Peptide chain group for the treatment of tumour individuation biological immune and its application in drug, the Antigenic Peptide chain group of the treatment tumour includes SEQ ID No：The combination of any one or at least two amino acid sequences in 1-100.The Antigenic Peptide chain group of the present invention can induce the blastomogenic Dendritic Cells of production, antigenic information thus can be presented to T cell as the Dendritic Cells of antigen presenting cell, to interact with T cell, so that T cell is generated specific killing tumour cell, play the role of killing tumor cell.
Description
Technical field
It is the invention belongs to malignant tumour biological immune technical field of pharmaceuticals, more particularly to a kind of for tumour individuation biology
The Antigenic Peptide chain group of immunization therapy and its application in drug.
Background technology
Currently, global Cancer Mortality rises increasingly, the death rate is high, poor prognosis.National Cancer Center whole nation tumour
Study on prevention office exists《International journal of cancer》Largest In China scale cancer Survival data Macro or mass analysis data are issued to show, in
5 years survival rates of state's cancer are 30.9%, horizontal far below developed country；The survival rate of rural patient is only City patient's simultaneously
Half.In developed country, prostate cancer, breast cancer occupy the majority, and in China, the cancers such as lung cancer, gastric cancer, liver cancer are more common, hair
Sick rate and the highest cancer of the death rate are lung cancer.The traditional therapies therapeutic effect such as operation, chemotherapy, radiotherapy is limited, patient 5 years
Survival rate is still relatively low；Especially eliminating side effect of radiotherapy and chemotherapy to is big, and patients ' life quality is poor, and survival rate is low.Biological immune treatment passes through machine
Body immune system killing tumor cell is the new therapy of future therapeutic tumour, has been increasingly becoming the heat for the treatment of tumour
Point.The more including common CIK cell immunization therapy of method of the tumour of biological immune treatment at present, DC medications treatment etc., but its
Therapeutic effect is not notable, and survival is not improved significantly.It is another have stimulated with not mutated tumour high-expression albumen
Immunocyte medication, research have anti tumor immune response, but due to its non-specificity expression, no doubt with the presence of side reaction, including
Eye-blurred, Hearing, fash etc..
Invention content
The object of the present invention is to provide a kind of Antigenic Peptide chain group for the treatment of tumour individuation biological immune and its in medicine
Application in object.
For this purpose, technical solution of the present invention is as follows：
In a first aspect, the present invention provides a kind of Antigenic Peptide chain group for treating tumour, the Antigenic Peptide chain group of the treatment tumour
Including SEQ ID No：The combination of any one or at least two amino acid sequences in 1-100, such as can be SEQ ID
No：Any one in 1-100, it is two arbitrary, three arbitrary, four arbitrary, it is arbitrary five until arbitrary 99 or all 100
The combination of item, since the limitation of length is no longer all enumerated herein.Particular sequence is as shown in table 1：
The Antigenic Peptide chain group of 1 present invention of table
Second aspect, the present invention provide a kind of pharmaceutical composition, and described pharmaceutical composition includes as described in relation to the first aspect
SEQ ID No：Any one in 1-100 or at least two amino acid sequences.
Preferably, described pharmaceutical composition is aqueous suspension, solution or solid state.Preferably, the solid state is
Uncoated or coated tablet form, such as pill, gel capsule, capsule or powder etc..
If described pharmaceutical composition is in drying regime, it can for example form sediment with one or more inert diluents
The mixing such as powder, cellulose, sucrose, lactose or silica.It can also include in the dry state other substances, such as a kind of
Or a variety of lubricants such as magnesium stearate or talcum powder, colorant, coating (sugar coated tablet) or varnish.If the drug of the present invention
Composition is liquid form, then it may include containing inert diluent such as water, ethyl alcohol, glycerine, vegetable oil or atoleine
Pharmaceutical solution, suspension, emulsion, syrup and elixir.Described pharmaceutical composition can also include in addition to diluent
Other liquid substances, such as wetting agent, sweetener, thickener, flavoring agent or stabilizer product.
Preferably, further include the auxiliary material pharmaceutically received.Preferably, the auxiliary material is excipient, diluent, carrier, tune
In taste agent, adhesive and filler any one or at least two combination, such as can be excipient, carrier and dilution
Agent, the combination of flavoring agent, adhesive and filler or diluent, carrier, flavoring agent, adhesive and filler, due to length
Limitation, the form of all combinations will not enumerate.
The third aspect, the Antigenic Peptide chain group that the present invention provides treatment tumour as described in relation to the first aspect are preparing treating cancer
Pharmaceutical composition in application.The cancer is the cancer (i.e. entity malignant tumour) of any kind, because the present invention
Antigenic Peptide chain group can induce the Dendritic Cells for generating tumour-specific, thus as the Dendritic Cells energy of antigen presenting cell
Antigenic information is presented to T cell, to interact with T cell, T cell is made to generate specific killing tumour cell, to
Play the role of killing tumor cell.
In the present invention, the cancer is preferably lung cancer, breast cancer, oophoroma, prostate cancer, melanoma, brain tumor, food
Pipe cancer, gastric cancer, liver cancer, cancer of pancreas, colorectal cancer, kidney, cutaneum carcinoma, spongioblastoma, neuroblastoma, sarcoma,
Embryonal-cell lipoma, osteochondroma, osteoma, osteosarcoma, seminoma, orchioncus, uterine cancer, H/N tumors, multiple marrow
Tumor, malignant lymphoma, polycythemia vera, leukaemia, thyroid tumors, tumor of ureter, tumor of bladder, gallbladder cancer,
In cholangiocarcinoma, chorioepithelioma or pediatric tumors any one or at least two combination.In addition, described pharmaceutical composition
It can also be with another or at least two anti-cancer agent in conjunction applications, such as arimedex (Letrozole and/or Anastrozole)
Deng.
Described pharmaceutical composition may be utilized independently or is used in combination with other drugs in given treatment, or with put
Penetrate therapy or operation joint.Specifically used method is：
(1) internal stimulus method：It is 7.4PBS (Hyclone) that the Antigenic Peptide chain group of the treatment tumour, which is dissolved in pH value,
In solution, concentration is adjusted to 2.5mg/ml, and covering 5%Aldara cream (iNova after 200ug are subcutaneously injected in each upper arm
Pharmaceuticals Australia Pty Ltd.), once a week, 12 weeks are a cycle.
(2) stimulated in vitro method：
0th day：(1) COBE Spectra blood analysis systems (U.S. Caridian BCT, Inc.) are used to carry out monokaryon
Cell detaches acquisition filter blood volume 2500-3500ml；(2) preparation 1LDC-CM culture solutions, 500mlX2 parts；(3) by cell from 4
Centrifuge tube is transferred in 500ml centrifuge tubes, is used in combination 10mlDC-CM to rinse former centrifuge tube, and be transferred to 500ml centrifuge tubes, is covered, mixes
It is even；(4) 25ml suction pipes are used, add 15mlDC-CM to each culture bottle；(5) concentration of IL-4 and GM-CSF, which is added, is all
1000IU/ml；(6) IL-4 is diluted, with 1%HAS to 1000IU/ml inside PBS.
6th day：The ripe mixed liquor of addition (7) dilutes IL-1 β, INF- α, IL-6 to 25ug/ml with 1%HSA-PBS；(8) eventually
Concentration：IL-1β10ng/ml,INF-α10ng/ml,IL-6 15ng/ml；(9) the diluting cells factor is in 44mlDC-CM, until last
Volume 50ml；(10) it inhales 1ml with aseptic straw and contains the DC-CM of cell factor to each culture bottle；(11) culture bottle is put
Enter incubator (37 DEG C, 5%CO2；± 10 DEG C, ± 0.5%CO2)。
The 7-8 days：Prepare the amount that peptide chain pulse culture solution (PPM) (12) calculates the PPM needed：Culture bottle quantity X30ml+
The amount for the PPM that 300ml=needs；(13) culture bottle is taken out from incubator, bottle inner cell is transferred to 500ml sterile centrifugations
Pipe；(14) culture bottle is rinsed with 30mlPPM, and flushing liquor is transferred to 500ml centrifuge tubes；(15) it is shifted with 2ml suction pipes all
Supernatant is used in combination 25mlPPM that cell is resuspended, the harvest pipe DC cells of harvest and flush pipe DC cells is merged into same pipe, indicates：
DC cell pipes；(16) one group of individuation specific mutations peptide chain that 1 pipe freezes is taken out, dissolves peptide chain with DC-PPM；(17) add peptide
Chain to DC manage, a concentration of 5ug/ml；(18) pine lid after be put into incubator (37 DEG C, 5%CO2；± 10 DEG C, ± 0.5%CO2), often
30min takes out incubator, mixing, 1.5 hours total times；(19) the DC cells for taking 0.2ml to be resuspended, are transferred in 12X75mm pipes,
Carry out endotoxin check and evaluation；(20) reduction of speed centrifuges, 1200rpm (309Xg), 7min, room temperature；(21) on being removed with 2ml suction pipes
Clear liquid；(22) individuation specificity DC cells are harvested, counts and is dissolved in 1mlPBS solution；(23) tumor-draining lymphode or
Injection in other.
Compared with prior art, at least provided by the present invention for the Antigenic Peptide chain group of tumour individuation biological immune treatment
It has the advantages that：It is described the present invention provides a kind of Antigenic Peptide chain group for treating tumour and its application in drug
The Antigenic Peptide chain group for treating tumour includes SEQ ID No：The group of any one or at least two amino acid sequences in 1-100
It closes.The Antigenic Peptide chain group of the present invention can induce the blastomogenic Dendritic Cells of production, thus as the dendron shape of antigen presenting cell
Antigenic information can be presented to T cell by cell, to interact with T cell, so that T cell is generated specific killing tumour thin
Born of the same parents play the role of killing tumor cell.After medication at least 6 weeks, it can obviously observe that tumour largely disappears by instrument, density
Thin out, variation is apparent；Incidence of side effects is small, less to the injury of patient.
Description of the drawings
Fig. 1 is HLA*A3101-HVKITDFGR Tetramer colored graphs before and after 1 medication of embodiment；
Fig. 2 is the tumour CT scan figure before and after 1 medication of embodiment；
Fig. 3 is the tumour CT scan figure before and after 2 medication of embodiment.
Specific implementation mode
Below in conjunction with the accompanying drawings and specific embodiment the present invention is described further, but following embodiments are absolutely not to this hair
It is bright to have any restrictions.
Embodiment 1
Patient A, female, 66 years old, adenocarcinoma of lung, hepatic metastases, the clinical IV phases were in progress after vinorelbine list medicine chemotherapy 6 times, target medicine
Drug resistance takes pulmonary lesions tissue biopsy, and after carrying out full exon sequencing and the detection of HLA typing chips, it is prominent that patient carries 19DEL
Become, HLA partings are HLA-A：A*2103A*3201；HLA-B：B*3217B*3102；HLA-C：C*0302C*0512；HLA-
DQB1：DQB1*0201DQB1*1221；HLA-DRB1：DRB1*0201DRB1*0601.
Use the specific tumor antigen peptide chain SEQ ID No of the present invention：1 is treated, 1 times a week, totally 12 weeks.Detection
Spot detection specific C D8+Tetramer+T cells secrete situation before and after injections of antigens peptide chain group (hereinafter referred to as " medication "), with
And changed by 12 weeks before and after imaging observation medication tumor sizes, as a result as depicted in figs. 1 and 2.
Fig. 1 is HLA*A3101-HVKITDFGR Tetramer colored graphs, wherein Fig. 1-A are colored graph before medication, CD8
+ Tetramer+T a concentration of 2.76%；Fig. 1-B are 6 weeks after stain chromatic graphs of medication, CD8+Tetramer+T a concentration of 3.52%；Figure
1-C is 12 weeks after stain chromatic graphs of medication, CD8+Tetramer+T a concentration of 6.2%；As can be seen that amount of speckle has from three group pictures
Significantly raised variation tendency, illustrates that the ratio (concentration) of tumor-killing cell CD8+Tetramer+T in blood significantly improves.
Fig. 2 is lung tumors CT figures before and after medication, and wherein Fig. 2-A are CT figures before medication, are left hilus pulumonis tumour, tumor size
For 4cm × 3cm；Fig. 2-B are that CT schemes after medication 12 weeks, it can be seen that tumour disappears substantially, and front and back variation is apparent.
Show that Antigenic Peptide chain group of the invention can induce the blastomogenic Dendritic Cells of production based on the above results, as anti-
Antigenic information can be presented to T cell by original in the Dendritic Cells of delivery cell, be interacted with T cell, so that T cell is generated special
Property killing tumor cell, plays the role of killing tumor cell, and with obvious effects.
Embodiment 2
Patient B, female, 62 years old, adenocarcinoma of lung, pleura metastasis, no operative indication, gemcitabine+carboplatin intravenous chemotherapy 6
Week, docetaxel chemotherapy are in progress after 2 periods, are in progress after partial interventional therapy.Carry out full exon sequencing and HLA typing chips
After detection, patient carries 19DEL mutation, and HLA partings are HLA-A：A*0303A*6501；HLA-B：B*0301B*3201；HLA-
C：C*0201C*0501；HLA-DQB1：DQB1*0202DQB1*0130；HLA-DRB1：DRB1*0312DRB1*1222.
Use the antigen peptide chain SEQ ID No of the treatment tumour of the present invention：2 are combined treatment, 1 times a week, totally 12 weeks.
Pretherapy and post-treatment lung tumors size variation situation is as shown in figure 3, as seen from Figure 3, before medication treatment, lobe of left lung is swollen
Tumor size 4cm × 6cm (Fig. 3-A)；12 weeks after medication treatment, lobe of left lung tumour disappears (Fig. 3-B) substantially, before tumour is compared with medication
It is obviously reduced, density is thin out.This example demonstrates that the Antigenic Peptide chain group of the present invention can induce the blastomogenic Dendritic Cells of production, make
Antigenic information can be presented to T cell for the Dendritic Cells of antigen presenting cell, interact with T cell, T cell is made to generate
Specific killing tumour cell plays the role of killing tumor cell, and with obvious effects.
Embodiment 3-100
Embodiment 3-100 takes variety classes, different degrees of cancer patient to carry out full exon sequencing and HLA parting cores
After piece detection, patient is to carry 19DEL mutation patients, is controlled respectively using the combining form of different Antigenic Peptide chain groups
It treats, once a week, totally 12 weeks.Before HLA*A3101-HVKITDFGR Tetramer coloration results of embodiment 3-100 and treatment
Lung tumors size variation situation is similar with embodiment 1-2 afterwards, and due to the limitation of length, it is no longer repeated herein.The above knot
The Antigenic Peptide chain group that the present invention can be explained in fruit can induce the blastomogenic Dendritic Cells of production, the dendron as antigen presenting cell
Antigenic information can be presented to T cell by shape cell, be interacted with T cell, and T cell is made to generate specific killing tumour cell,
Play the role of killing tumor cell, and with obvious effects.
During being treated to embodiment 1-100, with before ELISA detections antigen peptide chain, medication 3 weeks, 7 weeks, 11 weeks
Specific IFN-γ secretion situation, concrete outcome is as shown in table 1.
Comparative example 1-10
To comparative example 1-10 (carry out full exon sequencing and HLA typing chips detection after, patient be carry 19DEL
Mutation patient) treat during, before detecting medication with ELISA, medication 3 weeks, 7 weeks, 11 weeks specific IFN-γ secretion feelings
Condition, concrete outcome is as shown in table 2, and dosage is identical as embodiment 1-100；Wherein, comparative example 1-5 is added without peptide chain.
From table 2 it can be seen that embodiment 1-100,11 weeks after medication, the specific IFN-γ level of T cell secretion has
Significantly raised trend, illustrate to have used any one in the Antigenic Peptide chain group of the present invention or its arbitrarily combine and can increase cancer
The tumor-killing ability of disease peripheral blood in patients further demonstrates the effect of the present invention.And in comparative example 1-10, IFN-γ is horizontal
Also increased before and after medication, it may be possible to the effect of the nutritional ingredient of addition as a result, but all in all concentration increment it is far low
In embodiment 1-100, illustrate that it does not increase the tumor-killing ability of peripheral blood in patients or the ability of blood killing tumour is far low
In embodiment 1-100, the effect of the present invention is further demonstrated.
2 IFN-γ secretion of table counts list
Then, the rate of side effects of embodiment 1-100 is counted, the results are shown in Table 2, can from table 2
Go out, used the present invention Antigenic Peptide chain group after, the incidence (i.e. positive rate) of side reaction is relatively low, illustrate its side effect compared with
Small, the influence and injury to patient are relatively low.
2 rate of side effects statistical result of table
It should be noted that and understanding, the feelings of the spirit and scope of the present invention required by not departing from appended claims
Under condition, various modifications and improvements can be made to the present invention of foregoing detailed description.It is therefore desirable to the model of the technical solution of protection
It encloses and is not limited by given any specific exemplary teachings.
Applicant states that the above content is combine specific preferred embodiment made for the present invention further specifically
It is bright, and it cannot be said that specific implementation of the invention is confined to these explanations.For the ordinary skill of the technical field of the invention
For personnel, without departing from the inventive concept of the premise, a number of simple deductions or replacements can also be made, all should be considered as belonging to
In protection scope of the present invention.
Sequence table
<110>Tianjin Heng Jia biotechnologies Development Co., Ltd
<120>A kind of Antigenic Peptide chain group for treating tumour and its application in drug
<130> 15
<160> 100
<170> SIPOSequenceListing 1.0
<210> 1
<211> 8
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 1
Pro Val Ala Ile Lys Arg Glu Ala
1 5
<210> 2
<211> 8
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 2
Val Ala Ile Lys Arg Glu Ala Thr
1 5
<210> 3
<211> 8
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 3
Ala Ile Lys Arg Glu Ala Thr Ser
1 5
<210> 4
<211> 8
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 4
Ile Lys Arg Glu Ala Thr Ser Pro
1 5
<210> 5
<211> 8
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 5
Lys Arg Glu Ala Thr Ser Pro Lys
1 5
<210> 6
<211> 9
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 6
Ile Pro Val Ala Ile Lys Arg Glu Ala
1 5
<210> 7
<211> 9
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 7
Pro Val Ala Ile Lys Arg Glu Ala Thr
1 5
<210> 8
<211> 9
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 8
Val Ala Ile Lys Arg Glu Ala Thr Ser
1 5
<210> 9
<211> 9
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 9
Ala Ile Lys Arg Glu Ala Thr Ser Pro
1 5
<210> 10
<211> 9
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 10
Ile Lys Arg Glu Ala Thr Ser Pro Lys
1 5
<210> 11
<211> 9
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 11
Lys Arg Glu Ala Thr Ser Pro Lys Ala
1 5
<210> 12
<211> 10
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 12
Lys Ile Pro Val Ala Ile Lys Arg Glu Ala
1 5 10
<210> 13
<211> 10
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 13
Ile Pro Val Ala Ile Lys Arg Glu Ala Thr
1 5 10
<210> 14
<211> 10
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 14
Pro Val Ala Ile Lys Arg Glu Ala Thr Ser
1 5 10
<210> 15
<211> 10
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 15
Val Ala Ile Lys Arg Glu Ala Thr Ser Pro
1 5 10
<210> 16
<211> 10
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 16
Ala Ile Lys Arg Glu Ala Thr Ser Pro Lys
1 5 10
<210> 17
<211> 10
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 17
Ile Lys Arg Glu Ala Thr Ser Pro Lys Ala
1 5 10
<210> 18
<211> 10
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 18
Lys Arg Glu Ala Thr Ser Pro Lys Ala Asn
1 5 10
<210> 19
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 19
Val Lys Ile Pro Val Ala Ile Lys Arg Glu Ala
1 5 10
<210> 20
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 20
Lys Ile Pro Val Ala Ile Lys Arg Glu Ala Thr
1 5 10
<210> 21
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 21
Ile Pro Val Ala Ile Lys Arg Glu Ala Thr Ser
1 5 10
<210> 22
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 22
Pro Val Ala Ile Lys Arg Glu Ala Thr Ser Pro
1 5 10
<210> 23
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 23
Val Ala Ile Lys Arg Glu Ala Thr Ser Pro Lys
1 5 10
<210> 24
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 24
Ala Ile Lys Arg Glu Ala Thr Ser Pro Lys Ala
1 5 10
<210> 25
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 25
Ile Lys Arg Glu Ala Thr Ser Pro Lys Ala Asn
1 5 10
<210> 26
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 26
Lys Arg Glu Ala Thr Ser Pro Lys Ala Asn Lys
1 5 10
<210> 27
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 27
Lys Val Lys Ile Pro Val Ala Ile Lys Arg Glu Ala
1 5 10
<210> 28
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 28
Val Lys Ile Pro Val Ala Ile Lys Arg Glu Ala Thr
1 5 10
<210> 29
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 29
Lys Ile Pro Val Ala Ile Lys Arg Glu Ala Thr Ser
1 5 10
<210> 30
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 30
Ile Pro Val Ala Ile Lys Arg Glu Ala Thr Ser Pro
1 5 10
<210> 31
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 31
Pro Val Ala Ile Lys Arg Glu Ala Thr Ser Pro Lys
1 5 10
<210> 32
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 32
Val Ala Ile Lys Arg Glu Ala Thr Ser Pro Lys Ala
1 5 10
<210> 33
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 33
Ala Ile Lys Arg Glu Ala Thr Ser Pro Lys Ala Asn
1 5 10
<210> 34
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 34
Ile Lys Arg Glu Ala Thr Ser Pro Lys Ala Asn Lys
1 5 10
<210> 35
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 35
Lys Arg Glu Ala Thr Ser Pro Lys Ala Asn Lys Glu
1 5 10
<210> 36
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 36
Lys Val Lys Ile Pro Val Ala Ile Lys Glu Glu Thr
1 5 10
<210> 37
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 37
Val Lys Ile Pro Val Ala Ile Lys Glu Glu Thr Ser
1 5 10
<210> 38
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 38
Lys Ile Pro Val Ala Ile Lys Glu Glu Thr Ser Pro
1 5 10
<210> 39
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 39
Ile Pro Val Ala Ile Lys Glu Glu Thr Ser Pro Lys
1 5 10
<210> 40
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 40
Pro Val Ala Ile Lys Glu Glu Thr Ser Pro Lys Ala
1 5 10
<210> 41
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 41
Val Ala Ile Lys Glu Glu Thr Ser Pro Lys Ala Asn
1 5 10
<210> 42
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 42
Ala Ile Lys Glu Glu Thr Ser Pro Lys Ala Asn Lys
1 5 10
<210> 43
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 43
Ile Lys Glu Glu Thr Ser Pro Lys Ala Asn Lys Glu
1 5 10
<210> 44
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 44
Lys Glu Glu Thr Ser Pro Lys Ala Asn Lys Glu Ile
1 5 10
<210> 45
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 45
Glu Glu Thr Ser Pro Lys Ala Asn Lys Glu Ile Leu
1 5 10
<210> 46
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 46
Glu Thr Ser Pro Lys Ala Asn Lys Glu Ile Leu Asp
1 5 10
<210> 47
<211> 10
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 47
Glu Lys Ala Ser Pro Lys Ala Asn Lys Glu
1 5 10
<210> 48
<211> 10
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 48
Lys Ala Ser Pro Lys Ala Asn Lys Glu Ile
1 5 10
<210> 49
<211> 10
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 49
Ile Lys Glu Lys Ala Ser Pro Lys Ala Asn
1 5 10
<210> 50
<211> 10
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 50
Lys Glu Lys Ala Ser Pro Lys Ala Asn Lys
1 5 10
<210> 51
<211> 8
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 51
Val Ala Ile Lys Glu Glu Ala Thr
1 5
<210> 52
<211> 8
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 52
Ala Ile Lys Glu Glu Ala Thr Ser
1 5
<210> 53
<211> 8
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 53
Ile Lys Glu Glu Ala Thr Ser Pro
1 5
<210> 54
<211> 8
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 54
Lys Glu Glu Ala Thr Ser Pro Lys
1 5
<210> 55
<211> 8
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 55
Glu Glu Ala Thr Ser Pro Lys Ala
1 5
<210> 56
<211> 9
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 56
Pro Val Ala Ile Lys Glu Glu Ala Thr
1 5
<210> 57
<211> 9
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 57
Val Ala Ile Lys Glu Glu Ala Thr Ser
1 5
<210> 58
<211> 9
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 58
Ala Ile Lys Glu Glu Ala Thr Ser Pro
1 5
<210> 59
<211> 9
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 59
Ile Lys Glu Glu Ala Thr Ser Pro Lys
1 5
<210> 60
<211> 9
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 60
Lys Glu Glu Ala Thr Ser Pro Lys Ala
1 5
<210> 61
<211> 9
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 61
Glu Glu Ala Thr Ser Pro Lys Ala Asn
1 5
<210> 62
<211> 10
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 62
Ile Pro Val Ala Ile Lys Glu Glu Ala Thr
1 5 10
<210> 63
<211> 10
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 63
Pro Val Ala Ile Lys Glu Glu Ala Thr Ser
1 5 10
<210> 64
<211> 10
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 64
Val Ala Ile Lys Glu Glu Ala Thr Ser Pro
1 5 10
<210> 65
<211> 10
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 65
Ala Ile Lys Glu Glu Ala Thr Ser Pro Lys
1 5 10
<210> 66
<211> 10
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 66
Ile Lys Glu Glu Ala Thr Ser Pro Lys Ala
1 5 10
<210> 67
<211> 10
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 67
Lys Glu Glu Ala Thr Ser Pro Lys Ala Asn
1 5 10
<210> 68
<211> 10
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 68
Glu Glu Ala Thr Ser Pro Lys Ala Asn Lys
1 5 10
<210> 69
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 69
Lys Ile Pro Val Ala Ile Lys Glu Glu Ala Thr
1 5 10
<210> 70
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 70
Ile Pro Val Ala Ile Lys Glu Glu Ala Thr Ser
1 5 10
<210> 71
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 71
Pro Val Ala Ile Lys Glu Glu Ala Thr Ser Pro
1 5 10
<210> 72
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 72
Val Ala Ile Lys Glu Glu Ala Thr Ser Pro Lys
1 5 10
<210> 73
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 73
Ala Ile Lys Glu Glu Ala Thr Ser Pro Lys Ala
1 5 10
<210> 74
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 74
Ile Lys Glu Glu Ala Thr Ser Pro Lys Ala Asn
1 5 10
<210> 75
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 75
Lys Glu Glu Ala Thr Ser Pro Lys Ala Asn Lys
1 5 10
<210> 76
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 76
Glu Glu Ala Thr Ser Pro Lys Ala Asn Lys Glu
1 5 10
<210> 77
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 77
Val Lys Ile Pro Val Ala Ile Lys Glu Glu Ala Thr
1 5 10
<210> 78
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 78
Lys Ile Pro Val Ala Ile Lys Glu Glu Ala Thr Ser
1 5 10
<210> 79
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 79
Ile Pro Val Ala Ile Lys Glu Glu Ala Thr Ser Pro
1 5 10
<210> 80
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 80
Pro Val Ala Ile Lys Glu Glu Ala Thr Ser Pro Lys
1 5 10
<210> 81
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 81
Val Ala Ile Lys Glu Glu Ala Thr Ser Pro Lys Ala
1 5 10
<210> 82
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 82
Ala Ile Lys Glu Glu Ala Thr Ser Pro Lys Ala Asn
1 5 10
<210> 83
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 83
Ile Lys Glu Glu Ala Thr Ser Pro Lys Ala Asn Lys
1 5 10
<210> 84
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 84
Lys Glu Glu Ala Thr Ser Pro Lys Ala Asn Lys Glu
1 5 10
<210> 85
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 85
Glu Glu Ala Thr Ser Pro Lys Ala Asn Lys Glu Ile
1 5 10
<210> 86
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 86
Val Lys Ile Pro Val Ala Ile Lys Glu Lys Ala
1 5 10
<210> 87
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 87
Lys Ile Pro Val Ala Ile Lys Glu Lys Ala Ser
1 5 10
<210> 88
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 88
Ile Pro Val Ala Ile Lys Glu Lys Ala Ser Pro
1 5 10
<210> 89
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 89
Pro Val Ala Ile Lys Glu Lys Ala Ser Pro Lys
1 5 10
<210> 90
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 90
Val Ala Ile Lys Glu Lys Ala Ser Pro Lys Ala
1 5 10
<210> 91
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 91
Ala Ile Lys Glu Lys Ala Ser Pro Lys Ala Asn
1 5 10
<210> 92
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 92
Ile Lys Glu Lys Ala Ser Pro Lys Ala Asn Lys
1 5 10
<210> 93
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 93
Lys Glu Lys Ala Ser Pro Lys Ala Asn Lys Glu
1 5 10
<210> 94
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 94
Glu Lys Ala Ser Pro Lys Ala Asn Lys Glu Ile
1 5 10
<210> 95
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 95
Lys Ala Ser Pro Lys Ala Asn Lys Glu Ile Leu
1 5 10
<210> 96
<211> 10
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 96
Lys Ile Pro Val Ala Ile Lys Glu Lys Ala
1 5 10
<210> 97
<211> 10
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 97
Ile Pro Val Ala Ile Lys Glu Lys Ala Ser
1 5 10
<210> 98
<211> 10
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 98
Pro Val Ala Ile Lys Glu Lys Ala Ser Pro
1 5 10
<210> 99
<211> 10
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 99
Val Ala Ile Lys Glu Lys Ala Ser Pro Lys
1 5 10
<210> 100
<211> 10
<212> PRT
<213>Artificial sequence (artificial sequences)
<400> 100
Ala Ile Lys Glu Lys Ala Ser Pro Lys Ala
1 5 10
Claims (7)
1. a kind of Antigenic Peptide chain group for treating tumour, which is characterized in that the Antigenic Peptide chain group of the treatment tumour includes SEQ ID
No：The combination of any one or at least two amino acid sequences in 1-100.
2. a kind of pharmaceutical composition, which is characterized in that described pharmaceutical composition includes SEQ ID No described in claim 1：1-
Any one in 100 or at least two amino acid sequences.
3. pharmaceutical composition according to claim 2, which is characterized in that described pharmaceutical composition is aqueous suspension, solution
Or solid state.
4. pharmaceutical composition according to claim 3, which is characterized in that the solid state is uncoated or coated tablet
Form.
5. according to the pharmaceutical composition described in any one of claim 2-4, which is characterized in that further include pharmaceutically receive it is auxiliary
Material.
6. pharmaceutical composition according to claim 5, which is characterized in that the auxiliary material be excipient, diluent, carrier,
In flavoring agent, adhesive and filler any one or at least two combination.
7. Antigenic Peptide chain group the answering in the pharmaceutical composition for preparing treating cancer for the treatment of tumour according to claim 1
With.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810561361.1A CN108752424A (en) | 2018-06-04 | 2018-06-04 | A kind of Antigenic Peptide chain group for treating tumour and its application in drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810561361.1A CN108752424A (en) | 2018-06-04 | 2018-06-04 | A kind of Antigenic Peptide chain group for treating tumour and its application in drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108752424A true CN108752424A (en) | 2018-11-06 |
Family
ID=64002289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810561361.1A Withdrawn CN108752424A (en) | 2018-06-04 | 2018-06-04 | A kind of Antigenic Peptide chain group for treating tumour and its application in drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108752424A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101208354A (en) * | 2005-02-24 | 2008-06-25 | 安姆根有限公司 | epidermal growth factor receptor mutation |
| WO2016202963A2 (en) * | 2015-06-19 | 2016-12-22 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers |
-
2018
- 2018-06-04 CN CN201810561361.1A patent/CN108752424A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101208354A (en) * | 2005-02-24 | 2008-06-25 | 安姆根有限公司 | epidermal growth factor receptor mutation |
| WO2016202963A2 (en) * | 2015-06-19 | 2016-12-22 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers |
Non-Patent Citations (2)
| Title |
|---|
| WANG 等: "Human tumor antigens for cancer vaccine development", 《IMMUNOLOGICAL REVIEWS》 * |
| 杨帆 等: "肿瘤抗原肽及CTL杀伤机理的研究进展", 《中国肿瘤》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gu et al. | Enhancing anti-tumor immunity through liposomal oxaliplatin and localized immunotherapy via STING activation | |
| CN110248645B (en) | Exosome-based anticancer agents | |
| US9220763B2 (en) | Nano-vehicle derived from tumor tissue, and cancer vaccine using same | |
| US11154571B2 (en) | Exosomes sourced from granulocytic myeloid-derived suppressor cells and application thereof | |
| CN106974938B (en) | Exosome with anti-liver cancer effect and derived from mesenchymal stem cells and pharmaceutical preparation of exosome | |
| CN108440647A (en) | A kind of Antigenic Peptide chain group for treating tumour and its application in drug | |
| CN112334575A (en) | Method for obtaining animal model from conditional reprogramming cells and use of animal model for screening antitumor drugs | |
| CN110339350A (en) | A kind of antitumor drug combination compositions and its application | |
| CN108218961A (en) | A kind of Antigenic Peptide chain group for treating tumour and its application in drug | |
| CN108250269A (en) | A kind of Antigenic Peptide chain group for treating tumour and its application in drug | |
| CN108440646A (en) | A kind of Antigenic Peptide chain group for treating tumour and its application in drug | |
| CN108440648A (en) | A kind of Antigenic Peptide chain group for treating tumour and its application in drug | |
| CN108484731A (en) | A kind of Antigenic Peptide chain group for treating tumour and its application in drug | |
| Qin et al. | A novel biosynthesized vaccine based on tumor cells for peritoneal metastasis treatment in colon cancer | |
| CN108250268A (en) | A kind of Antigenic Peptide chain group for treating tumour and its application in drug | |
| US20240033302A1 (en) | Ganglioside gm3-containing nanoparticles as immunomodulators | |
| CN108047308A (en) | A kind of Antigenic Peptide chain group for treating tumour and its application in drug | |
| CN108752424A (en) | A kind of Antigenic Peptide chain group for treating tumour and its application in drug | |
| CN108440650A (en) | A kind of Antigenic Peptide chain group for treating tumour and its application in drug | |
| CN108440649A (en) | A kind of Antigenic Peptide chain group for treating tumour and its application in drug | |
| CN108484732A (en) | A kind of Antigenic Peptide chain group for treating tumour and its application in drug | |
| CN108440651A (en) | A kind of Antigenic Peptide chain group for treating tumour and its application in drug | |
| CN108715603A (en) | A kind of Antigenic Peptide chain group for treating tumour and its application in drug | |
| CN108484730A (en) | A kind of Antigenic Peptide chain group for treating tumour and its application in drug | |
| CN108409832A (en) | A kind of Antigenic Peptide chain group for treating tumour and its application in drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20181106 |
|
| WW01 | Invention patent application withdrawn after publication |